Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Post-Transplant Carfilzomib Plus Lenalidomide/Dexamethasone Provides Superior PFS Benefit Over Lenalidomide in Myeloma

August 26th 2022

Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.

Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma

August 26th 2022

The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26th 2022

The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.

Long-Term Treatment with Daratumumab Plus Lenalidomide/Dexamethasone Boosts OS Benefits in Myeloma

August 26th 2022

Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.

Daratumumab Plus KRd Induction and Consolidation With Tandem Transplant Has Feasibility in High-Risk Newly Diagnosed Myeloma

August 26th 2022

Induction and consolidation therapy with a combination comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.

Isatuximab Plus Pomalidomide and Dexamethasone Shows Meaningful PFS Benefit in Multiple Myeloma

August 26th 2022

Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.

Isatuximab-Based Regimens Demonstrate Favorable Safety in Relapsed/Refractory Multiple Myeloma

August 26th 2022

Isatuximab-containing regimens displayed favorable toxicity in patients with relapsed/refractory multiple myeloma in a real-world study.

Ixazomib Regimen Induces High Response Rates, Proves Tolerable in Relapsed/Refractory Multiple Myeloma

August 26th 2022

The addition of ixazomib to daratumumab, pomalidomide, and dexamethasone has elicited deep and durable response rates with a manageable safety profile as salvage therapy in patients with relapsed/refractory multiple myeloma.

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25th 2022

Patients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.

Clinical Implications of the IKEMA Trial in R/R MM

August 25th 2022

Dr Forsberg details the safety data and toxicity management strategies of the IKEMA clinical trial.

IKEMA Trial of Isatuximab plus Carfilzomib and Dexamethasone in R/R MM

August 25th 2022

Dr Peter Forsberg reviews clinical trial data on a triplet treatment regimen for relapsed/refractory multiple myeloma.

Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

August 25th 2022

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

August 25th 2022

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

European Commission Grants Conditional Marketing Authorization to Teclistamab for Multiple Myeloma

August 24th 2022

The European Commission has granted conditional marketing authorization to teclistamab for use as a single agent in adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Future Perspectives in Biomarker Identification and Testing in MM

August 24th 2022

Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.

Testing for Biomarkers in Multiple Myeloma

August 24th 2022

Two experts review strategies and barriers to overcome for biomarker testing in patients with multiple myeloma.

CART-ddBCMA Generates Deep Responses in Relapsed/Refractory Multiple Myeloma

August 19th 2022

Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.

European Commission Approves Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma

August 18th 2022

The European Commission has approved melphalan flufenamide for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies.

Elotuzumab Plus Pomalidomide and Dexamethasone Displays Sustained OS Benefit in Relapsed/Refractory Multiple Myeloma

August 18th 2022

Elotuzumab plus pomalidomide and dexamethasone demonstrated a significant improvement in overall survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma who previously received treatment with lenalidomide and a proteasome inhibitor.

Treatment Options for Patients with Multiple Myeloma in Early Relapse

August 18th 2022

An overview of the available treatment options in relapsed/refractory multiple myeloma.